<DOC>
	<DOCNO>NCT02635230</DOCNO>
	<brief_summary>The optimal antithrombotic therapy patient atrial fibrillation ( AF ) CHA2DS2-VASc score ≥1 concomitant acute coronary syndrome ( ACS ) revascularisation percutaneous coronary intervention ( PCI ) stenting , still unknown . For patient current North American European guideline recommend triple therapy strategy , include vitamin K antagonist ( VKA ) , aspirin clopidogrel . A major drawback triple therapy strategy significant increase risk major bleeding . Furthermore , ommitance aspirin introduction potent P2Y12 inhibitor well non-vitamin K oral anticoagulant ( NOAC ) , create numerous new antithrombotic treatment strategy patient overlap condition . To date , evidence risk benefit new antithrombotic treatment strategy lack . The WOEST 2 Registry aim improve medical care patient AF and/or heart valve prosthesis ánd undergo coronary revascularisation well understanding demographic , antithrombotic management related in-hospital long-term outcome . The WOEST 2 Registry provide data support benchmarking antithrombotic treatment pattern patient outcome . Objective : To assess different management pattern relate in-hospital long-term safety efficacy outcome combine use chronic oral anticoagulation P2Y12 inhibitor patient atrial fibrillation and/or heart valve prosthesis undergo coronary revascularisation .</brief_summary>
	<brief_title>What Optimal antiplatElet Anticoagulant Therapy Patients With Oral Anticoagulation Undergoing revasculariSaTion 2 .</brief_title>
	<detailed_description>The WOEST 2 Registry prospective , international , multi-centre , non-interventional , cohort study design recruit unselected cohort patient atrial fibrillation and/or heart valve prosthesis undergo coronary revascularisation . Trial overview Name : WOEST 2 REGISTRY Target enrollment : 2200 patient Time frame inclusion : within 72 hour index PCI coronory artery bypass grafting ( CABG ) Follow-up : 24 month Visits : 30 day , 12 24 month index PCI CABG</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>In order eligible include registry , subject must meet ALL follow criterion : 1 . Patient ≥ 18 year age ; 2 . Patients diagnosis atrial fibrillation ( prior hospitalisation ór hospitalisation within 72h coronary revascularisation ) and/or heart valve prosthesis ( aortic/mitral ) ; 3 . Chronic treatment OAC NOAC therapy inclusion intention start chronic treatment OAC NOAC within 72h coronary revascularisation AND intend duration treatment least one year inclusion registry ; 4 . Indication coronary revascularisation CABG PCI ( deployment least 1 coronary stent ) ; 5 . Prescription P2Y12 inhibitor ( clopidogrel , ticagrelor prasugrel ) CABG follow acute coronary syndrome* /or PCI ( deployment least 1 coronary stent ) . 6 . Patient provide write informed consent . A potential subject meet ANY follow criterion exclude participation study : 1 . Patients unable sign inform consent ( include mental disable patient ) ; 2 . Patients life expectancy &lt; 1 year ; 3 . Allergy intolerance P2Y12 inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Atrial Fibrillations</keyword>
	<keyword>Heart Valve Prostheses</keyword>
	<keyword>Acute Coronary Syndromes</keyword>
	<keyword>Percutaneous Coronary Revascularization</keyword>
	<keyword>Coronary Artery Bypass Grafting</keyword>
	<keyword>Coronary Artery Diseases</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Ischemic stroke</keyword>
	<keyword>Bleeding</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Embolism Thrombosis</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Prasugrel</keyword>
	<keyword>Antithrombotic treatment</keyword>
	<keyword>Oral anticoagulation</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Dabigatran etexilate mesylate</keyword>
	<keyword>Apixaban</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Direct Factor Xa Inhibitors</keyword>
	<keyword>Direct Thrombin Inhibitors</keyword>
</DOC>